Pharmacokinetic and bioequivalence testing of atorvastatin formulations in healthy male volunteers

Pharmazie

Volumn 61, Issue 9, 2006, Pages 805-806

  Mendoza, L ^a   Hajduch M ^b   Plausinaitis R ^a   Platilova V ^a   Emritte, N ^c   Svoboda, M ^a  

^a IQA as   (Czech Republic)

^b PALACKÝ UNIVERSITY   (Czech Republic)

^c Drogsan Pharmaceuticals   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYATORVASTATIN; ATORVASTATIN; DIVATOR; DRUG METABOLITE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG HALF LIFE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM ALLOWABLE CONCENTRATION; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AREA UNDER CURVE; BIOTRANSFORMATION; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MASS SPECTROMETRY; MIDDLE AGED; PYRROLES; THERAPEUTIC EQUIVALENCY;

EID: 33749010072     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (2)

1. Bocan TM, Ferguson E, McNally W et al. (1992) Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981: comparison with selected HMG-CoA reductase inhibitors. Biochim Biophys Acta 1123: 133-144.
2. Lea AP, McTavish D (1997) Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias. Drugs 53: 828-847.